Deal Roundup: EQT Life Sciences exits Tubulis to Gilead, Foresight scores 4x return selling TES to Legrand

EQT Life Sciences has exited its minority stake in Tubulis, a Germany-based clinical-stage biotech company developing next-generation antibody-drug conjugates.